Copy to clipboard 
Ossium Health announced the first surgery using its next-generation viable bone matrix, OssiGraft Prime. The launch of this innovative product represents a significant leap forward in orthopedic biologics, offering surgeons and patients meaningful advantages compared to traditional options.
The first surgery with OssiGraft Prime, an arthroscopic ankle fusion, required the graft to be precisely shaped and placed through a narrow incision. The product is now available throughout the U.S.
OssiGraft Prime builds upon the success of Ossium’s established OssiGraft viable bone matrix. Like the original product, OssiGraft Prime leverages Ossium’s donor screening, processing and decontamination protocols, minimizing the risk of infection and disease transmission. OssiGraft donors are far younger than other bone allografts, with a median age of 35 and maximum age of 55. Due to its vertebral bone source, OssiGraft also contains a high composition of cancellous bone, which may promote faster bone regeneration compared to legacy bone allografts that are rich in cortical bone.
This next-generation product incorporates processing advancements that yield a more cohesive product with a gum-like consistency that supports application in the intended location with precision and efficiency. The product stays in place and maintains its integrity during post-surgical irrigation.
“The successful first surgery using OssiGraft Prime is a testament to our unwavering commitment to building a healthier future,” said Kevin Caldwell, CEO, Co-Founder & President of Ossium Health. “With OssiGraft Prime, we bridged our innovative product development and tightly controlled manufacturing processes from cell therapies to orthopedic biologics, drawing on our unique expertise to deliver a product that represents a new standard of excellence in the OR. We’re extremely proud of OssiGraft Prime and its potential to drive improvements in bone healing and overall patient outcomes.”
Source: Ossium Health
Ossium Health announced the first surgery using its next-generation viable bone matrix, OssiGraft Prime. The launch of this innovative product represents a significant leap forward in orthopedic biologics, offering surgeons and patients meaningful advantages compared to traditional options.
The first surgery with OssiGraft Prime, an...
Ossium Health announced the first surgery using its next-generation viable bone matrix, OssiGraft Prime. The launch of this innovative product represents a significant leap forward in orthopedic biologics, offering surgeons and patients meaningful advantages compared to traditional options.
The first surgery with OssiGraft Prime, an arthroscopic ankle fusion, required the graft to be precisely shaped and placed through a narrow incision. The product is now available throughout the U.S.
OssiGraft Prime builds upon the success of Ossium’s established OssiGraft viable bone matrix. Like the original product, OssiGraft Prime leverages Ossium’s donor screening, processing and decontamination protocols, minimizing the risk of infection and disease transmission. OssiGraft donors are far younger than other bone allografts, with a median age of 35 and maximum age of 55. Due to its vertebral bone source, OssiGraft also contains a high composition of cancellous bone, which may promote faster bone regeneration compared to legacy bone allografts that are rich in cortical bone.
This next-generation product incorporates processing advancements that yield a more cohesive product with a gum-like consistency that supports application in the intended location with precision and efficiency. The product stays in place and maintains its integrity during post-surgical irrigation.
“The successful first surgery using OssiGraft Prime is a testament to our unwavering commitment to building a healthier future,” said Kevin Caldwell, CEO, Co-Founder & President of Ossium Health. “With OssiGraft Prime, we bridged our innovative product development and tightly controlled manufacturing processes from cell therapies to orthopedic biologics, drawing on our unique expertise to deliver a product that represents a new standard of excellence in the OR. We’re extremely proud of OssiGraft Prime and its potential to drive improvements in bone healing and overall patient outcomes.”
Source: Ossium Health
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.
